Physician profile
Todd M Waldmann
NPI 1104877299
$2,686.14
in general payments reported to CMS, 2019-2025
17 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.60 · 2020: $85.55 · 2021: $88.86 · 2022: $1,755 · 2023: $384 · 2024: $126 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628 · Education: $93.00 · Debt Forgiveness: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.05 |
| Education | $93.00 |
| Debt Forgiveness | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sn Holdings, LLC | $1,861.21 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.69 | 2021-2025 | |
| Janssen Biotech, INC. | $111.77 | 2023-2025 | Erleada, Carvykti, Rybrevant |
| Astellas Pharma US INC | $107.76 | 2023-2025 | Myrbetriq, Veozah |
| Urogpo LLC | $98.15 | 2019-2020 | |
| Olympus America INC. | $62.40 | 2025 | Itind System |
| Urogen Pharma, INC. | $51.96 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $38.96 | 2023 | Lynparza, Keytruda |
| Dendreon Pharmaceuticals LLC | $36.55 | 2023 | Provenge |
| Boston Scientific Corporation | $35.38 | 2022 | |
| Laborie Medical Technologies Corp. | $29.42 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Intuitive Surgical, INC. | $26.49 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.34 | 2022 | |
| Bioprotect Medical, INC. | $18.93 | 2025 | Bioprotect Balloon Implant System |
| Telix Pharmaceuticals | $16.80 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.51 | 2024 | |
| Travere Therapeutics, INC. | $11.82 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$484,622.74 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Waldmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.